China has become a dominant global supplier of pharmaceutical ingredients, raising concerns in Western policy circles about potential leverage. The country supplies 40% of active pharmaceutical ingredients (APIs) worldwide, and nearly 41% of key starting materials (KSMs) for US-approved drugs come exclusively from China. Think tanks in Washington, such as the Brookings Institution and the Council on Foreign Relations, have warned that this dependency could give Beijing significant influence, similar to its dominance in rare earths. Consequently, organizations like the Atlantic Council are urging the US and its allies to bolster supply chain resilience and reduce reliance on Chinese pharmaceutical inputs. AI
RANK_REASON Policy discussion and analysis regarding supply chain dependency on a major global producer. [lever_c_demoted from significant: ic=1 ai=0.1]
- Atlantic Council
- Beijing
- Brookings Institution
- China
- Council on Foreign Relations
- European Union
- India
- Mexico
- US
- Washington
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
